Neuroepo multisession
Resting-state EEG recorded from 25 patients with Parkinson's disease enrolled in a double-blind, randomized, placebo-controlled trial of Neuroepo, an erythropoietin formulation with low sialic acid content. Participants received Neuroepo (n=15) or placebo (n=10), and EEG was recorded before and six months after administration. Raw data are provided in EEG-BIDS format to support assessment of qualitative and quantitative EEG (source-level) biomarkers of neuroprotection.
- Participants
- 15
- Channels
- 19 (10-20)
- Size
- 189 MB
- Version
- v1.0.0
- Updated
- May 13, 2026